ライフサイエンスコーパス: PAF receptor

1 lease of microvesicles is dependent upon the PAF receptor.

2 hat ChoP+ NTHi bacilli co-localized with the PAF receptor.

3 human epidermal cell line KB with the human PAF receptor.

4 chial cells by means of interaction with the PAF receptor.

5 tion, because such compounds can bind to the PAF receptor.

6 that this inhibition is not mediated by the PAF receptor.

7 cells yielded the predicted amplicon for the PAF receptor.

8 cci are consistently independent of CD14 and PAF receptor.

9 n from which they co-immunoprecipitated with PAF receptor.

10 atelet aggregation via interactions with the PAF receptor.

11 These cells expressed the PAF receptor.

12 antagonists indicated signaling through the PAF receptor.

13 been prepared and evaluated using the cloned PAF receptor.

14 they are not mediated through an endogenous PAF receptor.

15 ive protein, a class of myeloma proteins and PAF receptors.

16 ion which was dependent on the expression of PAF receptors.

17 ual affinity for histamine H1 -receptors and PAF receptors.

18 on of these derivatives as assayed by cloned PAF receptors.

19 include CD14 and platelet-activating factor (PAF) receptor.

20 tagonists of the platelet-activating factor (PAF) receptor.

21 tagonists of the platelet-activating factor (PAF) receptor.

22 bind to a cloned platelet-activating factor (PAF) receptor.

23 expressing human platelet-activating factor (PAF) receptors.

24 An anti-PAF receptor Ab led to a significant decrease in miltefo

25 Because PAF receptor activation has been shown to affect the dev

26 ortance of the 7-position of ginkgolides for PAF receptor activity.

27 ssing KB cells with the metabolically stable PAF receptor agonist carbamoyl-PAF resulted in increased

28 factor endothelin-1 and the nonhydrolyzable PAF receptor agonist carbamyl-PAF.

29 examines the effects of the nonhydrolyzable PAF receptor agonist methyl carbamyl PAF (mc-PAF) on the

30 ukocytes (PMNs) were a significant source of PAF receptor agonists after stimulation by either class

31 Production of PAF receptor agonists required that the PMN adhere to a

32 epithelial cell line stably transfected with PAF receptor also showed little evidence that cis-UCA st

33 cular dynamic simulation of HPC docking into PAF receptor and by comparison of its leishmanicidal fun

34 roups still retained binding affinity to the PAF receptor and hence should be promising ligands for p

35 .), implying that this response involves the PAF receptor and is not due to a detergent-like effect o

36 owed little evidence that cis-UCA stimulated PAF receptor and it did not bind to this receptor.

37 o alpha toxin which was mediated through the PAF receptor and P-selectin.

38 and human BMEC in a manner dependent on the PAF receptor and the presence of pneumococcal choline-bi

39 B2 subtype), histamine (an H1 subtype), and PAF receptors and exhibit very similar immunocytochemica

40 [(3)H]PAF clearance was unchanged in PAF receptor(-/-) animals, or over the first 2 half-live

41 RBL cell extracts and human whole blood, and PAF receptor antagonism in a receptor binding assay.

42 In Expt 2 (conducted at 30 degrees C), the PAF receptor antagonist BN 52021 (29 micromol kg-1, i.v.

43 The effect of PAF was receptor mediated, as PAF receptor antagonist BN52021 blocked the effect.

44 Similarly, a PAF receptor antagonist did not inhibit cis-UCA-induced

45 PAF receptor antagonist had no effect under any conditio

46 Pretreatment of bronchial cells with a PAF receptor antagonist inhibited invasion by NTHi 2109

47 The PAF receptor antagonist LAU-8080 inhibited bFGF-stimulat

48 n by lysoPAF is not affected by the use of a PAF receptor antagonist or genetic deletion of the PAF r

49 as it was dose dependently inhibited by the PAF receptor antagonist WEB 2086 and blocked by pertussi

50 r and affinity of binding sites for specific PAF receptor antagonist WEB2086 were identical in membra

51 n; the hetrazepine BN50730 (an intracellular PAF receptor antagonist) also inhibits both NMDA-stimula

52 r zileuton (a 5-LO inhibitor) or BN 50739 (a PAF receptor antagonist), and it demonstrated the same i

53 ells by a mechanism inhibitable by CV3988, a PAF receptor antagonist, and by PAF itself.

54 otein kinase A (PKA) and was attenuated by a PAF receptor antagonist, blocking downstream activity.

55 s 25-fold less potent than ginkgolide B as a PAF receptor antagonist, due to the presence of the 7bet

56 etreated with a specific mediator inhibitor (PAF receptor antagonist, n = 6; prostacyclin antibody, n

57 , which was ameliorated in the presence of a PAF receptor antagonist.

58 co-incubation with PAF acetylhydrolase, or a PAF receptor antagonist.

59 of the TTLs, ginkgolide B is the most potent PAF receptor antagonist.

60 of rats with the platelet-activating factor (PAF) receptor antagonist UK-74,505 or the antihuman inte

61 , or WEB 2170, a platelet-activating factor (PAF) receptor antagonist, inhibited ALI caused by D.42 p

62 AU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is highly neuroprotective in a

63 O) inhibitor and platelet-activating factor (PAF) receptor antagonist.

64 Pretreatment of endotoxemic rats with PAF receptor antagonists BN 50739 or WEB 2170 reduced se

65 Our findings indicate that PAF receptor antagonists convey protection against hepat

66 eceptor-deficient mice or mice injected with PAF receptor antagonists failed to induce LC migration.

67 We confirm that PAF receptor antagonists inhibit proliferation of HUVEC

68 nuated by PAF receptor antagonists, and that PAF receptor antagonists inhibit the migration and invas

69 Pretreatment with PAF receptor antagonists inhibited both carbamoyl-PAF-in

70 latelet-activating factor (PAF) pathway with PAF receptor antagonists prevents TER119-driven changes

71 re, anti-TGF-beta antibody, indomethacin, or PAF receptor antagonists restored cytokine production in

72 tic photoactivatable substituents are potent PAF receptor antagonists with K(i) values of 0.09-0.79 m

73 gration and invasion, which is attenuated by PAF receptor antagonists, and that PAF receptor antagoni

74 n and demonstrated the administration of the PAF receptor antagonists, BN 50739 and WEB 2170, inhibit

75 duced CHO elongation was blocked by specific PAF receptor antagonists, BN52021 and SR27417.

76 8 production that was partially inhibited by PAF receptor antagonists.

77 d when UV-irradiated mice were injected with PAF receptor antagonists.

78 HO elongation by platelet-activating factor (PAF) receptor antagonists and secretion of PAF by human

79 B-2086 (specific platelet activating factor (PAF) receptor antagonists), suggesting that they are not

80 nd PAF-like phospholipids that also bind the PAF receptor are implicated in numerous pathological sit

81 the present study, we sought to determine if PAF receptors are present on human bronchial epithelial

82 th inhibits leukotriene synthesis and blocks PAF receptor binding may provide therapeutic advantages

83 PAF receptor blockade significantly increased systemic h

84 protein-coupled platelet-activating factor (PAF) receptor, blocked the action of oxLDL.

85 PDT-generated MVPs were independent of the PAF receptor but were dependent on the MVP-generating en

86 tagonists of the platelet-activating factor (PAF) receptor but not inhibitors of PAF synthesis.

87 ngs suggest that hippocampal plasma membrane PAF receptors, but not intracellular PAF binding sites,

88 asts express the platelet-activating factor (PAF) receptor, but its role is unclear.

89 for clarifying the binding of ginkgolides to PAF receptor by photolabeling studies.

90 zed phospholipids that are recognized by the PAF receptor can trigger inflammatory and thrombotic eve

91 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-UCA-induced immune suppressi

92 ive TTLs and their derivatives to the cloned PAF receptor, confirming that of the TTLs, ginkgolide B

93 nts suggest that the stimulation of neuronal PAF receptors could be one crucial step for the regulati

94 for either intracellular or plasma membrane PAF receptors decreased the late-phase of the nociceptiv

95 comparison of its leishmanicidal function on PAF receptor-deficient macrophages and mice under HPC tr

96 hat compared with wild-type macrophages, the PAF receptor-deficient macrophages showed 1) reduced bin

97 In contrast, applying DNFB to PAF receptor-deficient mice or mice injected with PAF re

98 nsitivity response generated in wild-type or PAF receptor-deficient mice was identical.

99 C+, CD11c+, Langerin+) in the lymph nodes of PAF receptor-deficient mice was significantly depressed

100 ontrary to the diminution of LC migration in PAF receptor-deficient mice, we did not observe any diff

101 , CD11c+, Langerin-) into the lymph nodes of PAF receptor-deficient mice.

102 antly compromised leishmanicidal function in PAF receptor-deficient mice.

103 anscytose bacteria across the cell while non-PAF receptor entry shunts bacteria for exit and reentry

104 Ultraviolet B irradiation of PAF-receptor-expressing KB cells resulted in significant

105 Treatment of PAF-receptor-expressing KB cells with the metabolically

106 Similarly, treatment of the PAF-receptor-expressing primary cultures of human kerati

107 platelet-activating factor (PAF) content and PAF receptor expression in human breast cancer cells and

108 PAF-like lipids, which might not require the PAF receptor for their signaling.

109 ceptor antagonist or genetic deletion of the PAF receptor gene.

110 we surmised that platelet-activating factor (PAF) receptor had a significant role in the antileishman

111 Overexpression of the PAF receptor in primary human keratinocytes also enhance

112 These results indicate significant roles for PAF receptor in the leishmanicidal activity of HPC.

113 Corneal myofibroblasts express a PAF receptor in the nuclear membrane, and they also expr

114 Expression of the PAF receptor in the PAF receptor-negative epidermoid cel

115 we examined the involvement of 5-HT(2A) and PAF receptors in the ability of cis-UCA to stimulate imm

116 The expression of PAF receptors in these cells was further confirmed by re

117 rway epithelial cells through stimulation of PAF receptors includes up-regulation of the nuclear tran

118 Saturable PAF receptor-independent transport, rather than just int

119 Inhibition of TASK-1 via activation of the PAF receptor is protein kinase C (PKC)-dependent.

120 rmal cell damage and epidermal cells express PAF receptors, it is not known whether PAF is involved i

121 tress, and many epidermal carcinomas express PAF receptors, it is not known whether PAF is involved i

122 ctivation of the platelet-activating factor (PAF) receptor leads to a decrease in outward current in

123 F was just 10-fold less potent than PAF as a PAF receptor ligand and agonist.

124 The identity and distribution of the PAF receptor ligand in endotoxemia is unknown.

125 ce of a photosensitizer, fragmentation to C4-PAF receptor ligands.

126 oxidative stress, and keratinocytes express PAF receptors linked to cytokine biosynthesis, it is not

127 oxidative stress, and keratinocytes express PAF receptors linked to cytokine biosynthesis, it is not

128 These studies suggest that the epidermal PAF receptor may be a pharmacologic target for ultraviol

129 Blocking pathologic activation of PAF receptors may therefore be a pivotal step in the tre

130 roducts that are no longer recognized by the PAF receptor, may be a particularly important signal ter

131 t on specific cellular responses that can be PAF receptor mediated, involves signaling through 5-LO t

132 sponse which was platelet-activating factor (PAF) receptor-mediated, involved signaling through prote

133 eletion, phosphorylation-deficient mutant of PAF receptor (mPAFR) when compared with the wild-type re

134 ptor to remove phosphorylation sites (mutant PAF receptor, mPAFR) results in enhancement of PAF-stimu

135 revealed amplification products derived from PAF receptor mRNA corresponding to transcripts 1 and 2.

136 Immunofluorescence with a PAF-receptor (N terminus) polyclonal antibody showed tha

137 using PAF antagonists or toxin challenge of PAF receptor negative mice reversed or ameliorated many

138 Expression of the PAF receptor in the PAF receptor-negative epidermoid cell line KB augmented

139 d by retroviral mediated transduction of the PAF receptor-negative human epidermal carcinoma cell lin

140 d by retroviral-mediated transduction of the PAF receptor-negative human epidermal cell line KB with

141 d by retroviral-mediated transduction of the PAF receptor-negative human epidermal cell line KB with

142 d by retroviral-mediated transduction of the PAF-receptor-negative human epidermal cell line KB with

143 LC chimerism indicates that the PAF receptor on keratinocytes but not LCs is responsible

144 the interaction of endothelial cell PAF with PAF receptors on circulating cells, these data suggest t

145 The presence of PAF receptors on the pancreatic vascular endothelium pro

146 The results demonstrate the localization of PAF receptors on the pancreatic vascular endothelium.

147 tagonists of the platelet-activating factor (PAF) receptor on the BMEC.

148 at although cell walls bind to both CD14 and PAF receptor, only CD14 appears to engender a cytokine r

149 vating factor (PAF) increases in LE and that PAF receptor (PAF-r) ablation mitigates its progression.

150 ted in increased reactive oxygen species and PAF receptor (PAF-R) agonistic activity in comparison wi

151 dermal carcinoma cell line KB with the human PAF receptor (PAF-R) and ablation of the endogenous PAF-

152 We demonstrate that PAF receptor (PAF-R) immunoreactivity and mRNA are detec

153 etter insight into the role of the epidermal PAF receptor (PAF-R) in UVB-mediated gene expression, Af

154 em created by retroviral transduction of the PAF receptor (PAF-R) into the PAF-R-negative human epide

155 human epidermal cell line KB with the human PAF receptor (PAF-R).

156 human epidermal cell line KB with the human PAF receptor (PAF-R).

157 These substances exert effects through the PAF receptor (PAF-R).

158 tress, and many epidermal carcinomas express PAF receptors (PAF-R) linked to cytokine production, it

159 mation, and keratinocytes express functional PAF receptors (PAF-R).

160 oxidized glycerophosphocholines that act as PAF-receptor (PAF-R) agonists.

161 F) were implanted in corneas of wild-type or PAF-receptor (PAF-R)-knockout mice, and the progression

162 ted with an expression plasmid for the human PAF receptor, PAF stimulation increased AP-1 DNA binding

163 Using mice lacking the PAF receptor (PAFR(-/-)), we investigated the relevance

164 UVB exposure and PAF receptor (PAFR) activation in keratinocytes induce t

165 kemia RBL-2H3 cell line expressing wild-type PAF receptor (PAFR) and a phosphorylation-deficient muta

166 ice were injected with PCA 4248, a selective PAF receptor (PAFR) antagonist, transfer of tolerance wa

167 FGF-2 supplementation, PAF receptor (PAFR) blockade with WEB-2086, and inactiva

168 rmation of lipid mediators that signaled the PAF receptor (PAFR) in fully differentiated human cells

169 peptide chemoattractants, cDNA encoding the PAF receptor (PAFR) was co-expressed into RBL-2H3 cells

170 human melanoma cell lines, and we found that PAF receptor (PAFR) was expressed in all eight lines.

171 establishing intracellular signaling via the PAF receptor (PAFR).

172 ctions by interacting with G protein-coupled PAF receptors (PAFR).

173 hypothesize that platelet-activating factor (PAF) receptor (PAFR) ligation requires CME and causes en

174 , suggesting that it may act through the PAF/PAF receptor pathway previously shown to have anti-Leish

175 Consistent with the PAF receptor phosphorylation, both thrombin and thrombin

176 et-B-induced interleukin-8 production in the PAF-receptor-positive cells, but not in control KB cells

177 est that interaction of pneumococci with the PAF receptor results in sorting so as to transcytose bac

178 tibody directed toward the N-terminus of the PAF receptor revealed specific localization to the vascu

179 at the third intracellular domain of the rat PAF receptor (rPAFR) is a critical determinant in its co

180 ammatory lipid mediator, we propose that the PAF receptor senses cellular damage through the recognit

181 Pharmacological testing with cloned PAF receptors showed that ginkgolides with 7alpha-substi

182 d sphingomyelinase and genetic inhibition of PAF receptor signaling.

183 bath application of BN 52021 and trans-BTD, PAF receptor-specific antagonists.

184 vement of signaling intermediates in the PAF-PAF receptor system in the induction of TIMP2 and MT1-MM

185 ids, creating PAF analogs that stimulate the PAF receptor to induce further PAF synthesis and apoptos

186 diator that interacts with G protein-coupled PAF receptors to elicit diverse physiological and pathop

187 ell types within the pancreas expressing the PAF receptor using immunohistochemical protocols.

188 ial cells were isolated and examined for the PAF receptor using immunohistochemistry, reverse transcr

189 indicating that activation of the epidermal PAF receptor was linked to interleukin-8 production.

190 ine the mechanism by which UVB activates the PAF receptor, we used mass spectrometry to demonstrate s

191 Blocking the PAF receptor with LAU-0901 inhibited the synergistic eff